RecruitingNCT06960954

PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma

Prothrombin Induced by Vitamin K Absence II (PIVKA-II) Serum Level as a Predictor for Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma Patients.

Sponsor

Tanta University

Enrollment

116 participants

Start Date

Jan 15, 2025

Study Type

OBSERVATIONAL

Conditions

Hepato Cellular Carcinoma (HCC)Portal Vein Tumour Thrombosis

Summary

The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma (HCC) patients. Researchers will compare PIVKA-II serum levels in HCC patients with PVTT and without PVTT. Participants will undergo history-taking, clinical examination, laboratory investigations, PIVKA-II serum level, Child-Pugh classification, Model for End-stage Liver Disease (MELD) score, BCLC staging, abdominal ultrasonography, and Triphasic CT abdomen with contrast or MRI to evaluate tumor site, size, number, and presence of PVTT (a filling defect in the portal vein or its branch to distinguish PVTT or thrombus).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether a protein marker in the blood called PIVKA-II can predict the development of a blood clot in the portal vein (the main vein leading to the liver) in patients with liver cancer (HCC). It's an observational study — no new treatment is being tested. **You may be eligible if...** - You are over 18 years old - You have been diagnosed with liver cancer (HCC), with or without a portal vein clot, confirmed by imaging or biopsy **You may NOT be eligible if...** - You have had prior local liver treatments or a liver transplant - You take vitamin K, blood thinners (vitamin K antagonists), or antibiotics - You have bile duct blockage (cholestasis) - You have kidney insufficiency - You have another type of cancer - You are unwilling to participate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTProthrombin induced by vitamin K absence II (PIVKA-II)

Serum PIVKA-II level will be measured in HCC patients with and without PVTT.

Locations(1)

Tanta University Hospitals

Tanta, Gharbyea, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06960954

Related Trials

SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin

NCT075605661 location

A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma

NCT073280091 location

Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma

NCT075367891 location

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

NCT0699065914 locations

Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma

NCT073029193 locations